相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial
Karl Andersen et al.
JOURNAL OF HYPERTENSION (2008)
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension
Yagiz Uresin et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2007)
Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis
Matthew R. Weir et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2007)
Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects
Sujata Vaidyanathan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension
Byung-Hee Oh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Thorough QT study with recommended and supratherapeutic doses of tolterodine
B. K. Malhotra et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
QT effects of duloxetine at supratherapeutic doses: A placebo and positive controlled study
Lu Zhang et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment
Sujato Vaidyanathan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment
Sujata Vaidyanathan et al.
CLINICAL PHARMACOKINETICS (2007)
Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects
Sujata Vaidyanathan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers
S. Vaidyanathan et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Clinical trial design to evaluate the effects of drugs on cardiac repolarization: Current state of the art
AJ Camm
HEART RHYTHM (2005)
QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder
DB Serra et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males
H Stass et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients
AH Gradman et al.
CIRCULATION (2005)
Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation
V Piotrovsky
AAPS JOURNAL (2005)
Drug-induced Torsades de Pointes and implications for drug development
RR Fenichel et al.
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (2004)
Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes
N Abi-Gerges et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2004)
Drug therapy: Drug-induced prolongation of the QT interval
DM Roden
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects
S Burriere et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Evaluation of Vardenafil and Sildenafil on cardiac repolarization
J Morganroth et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
What clinicians should know about the QT interval
SM Al-Khatib et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Circadian profile of QT interval and QT interval variability in 172 healthy volunteers
H Bonnemeier et al.
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY (2003)
Induced QT prolongation and torsades de pointes
YG Yap et al.
HEART (2003)
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren
A Stanton et al.
HYPERTENSION (2003)
How to correct the QT interval for the effects of heart rate in clinical studies
P Davey
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2002)
Drug-induced prolongation of the OT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity
RR Shah
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2002)
The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes
M Malik
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY (2002)
Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death
AH Glassman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Evaluation of drug-induced QT interval prolongation - Implications for drug approval and labelling
M Malik et al.
DRUG SAFETY (2001)
Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome
MD Drici et al.
DRUG SAFETY (2001)
分享论文
